Lundbeck to present eight new analyses on bexicaserin at AES 2025, reinforcing sustained seizure-reduction potential across DEEs
Lundbeck A/S (Lundbeck) announced that new pipeline data regarding bexicaserin (LP352), a novel investigational drug for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs), will… read more.
